Keratoconjunctivitis sicca (Dry Eye) Therapeutic Pipeline Market Review, H2 2016

Keratoconjunctivitis sicca (Dry Eye) Treatment Pipeline Review H2 2016

‘Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016’, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects.

Request a sample report @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)
- The report reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Keratoconjunctivitis sicca (Dry Eye) therapeutics and enlists all their major and minor projects
- The report assesses Keratoconjunctivitis sicca (Dry Eye) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @

Key points in table of content
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Keratoconjunctivitis sicca (Dry Eye) Overview 9
Therapeutics Development 10
Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Overview 10
Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis 11
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Development by Companies 12
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Investigation by Universities/Institutes 16
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Keratoconjunctivitis sicca (Dry Eye) - Products under Development by Companies 21
Keratoconjunctivitis sicca (Dry Eye) - Products under Investigation by Universities/Institutes 25
Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development 26
AB2 Bio Ltd. 26
Allergan Plc 27
Ascendia Pharmaceuticals LLC 28
Chong Kun Dang Pharmaceutical Corp. 29
Digna Biotech, S.L. 30
Dompe Farmaceutici S.p.A. 31
HanAll Biopharma Co., Ltd. 32
Herantis Pharma Plc 33
Huons Co., Ltd. 34
InSite Vision Incorporated 35
Kala Pharmaceuticals, Inc. 36
Kissei Pharmaceutical Co., Ltd. 37

Get this report @

Contact Info:
Email: Send Email
Organization: WiseGuy Research Consultant Pvt Ltd
Address: WISE GUY RESEARCH CONSULTANTS PVT LTD Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India Ph: +91 841 198 5042
Phone: +1-646-845-9349 (US) +44 208 133 9349 (UK)t

Release ID: 140080